Innoviva (INVA) Specialty Therapeutics, a subsidiary of Innoviva, announced the United States commercial availability of ZEVTERA, the newest addition to the company’s growing antibiotic portfolio. ZEVTERA is the only U.S. FDA approved advanced-generation cephalosporin indicated to treat adult patients with Staphylococcus aureus bloodstream infection, including those with right-side endocarditis caused by methicillin-susceptible and methicillin-resistant isolates. ZEVTERA is the latest approved MRSA SAB therapy since 2006.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INVA: